NCT Number: NCT00102817
Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children
This trial is conducted in the United States of America (USA). This is a 12 month study to determine if Norditropin is safe and effective in children with IGF deficiency.
Looking for future studies?
Notify MeKey information
Conditions
Age range
3 year–13 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Novo Nordisk Investigational Site, Los Angeles, California, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Ages 3-15
- Presence of growth failure indicated by height standard deviation score less than equal to -2
- Body mass index greater than or equal to 25th percentile for height age
- IGF concentration less than or equal to 33rd percentile
Treatment and study plan
Primary outcomes
-
Change in height standard deviation score
Time frame: 12 months
Secondary outcomes
-
12 months change in height standard deviation score adjusted for parent height z-score
Sponsors and collaborators
Lead sponsor
Novo Nordisk A/S
Industry
Registry information
Official study title
Somatropin (Norditropin) in Children With Growth Failure Associated With ICF Deficiency.
Important dates
- Study start
- 2003
- Primary completion
- 2006
- Study completion
- 2006
- First posted
- Feb 2, 2005
- Registry last updated
- Jan 18, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)
NCT01009905
Bone Diseases, Bone Diseases, Developmental
Plainsboro, New Jersey, United States
View Trial DetailsEffect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients
NCT01562834
Adult Growth Hormone Deficiency, Bone Diseases
Angers, France
View Trial DetailsA Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency
NCT01706783
Adult Growth Hormone Deficiency, Bone Diseases
Århus C, Denmark
View Trial DetailsFirst Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects
NCT01514500
Adult Growth Hormone Deficiency, Bone Diseases
Neuss, Germany
View Trial Details